TAS-108

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C33H47NO3.C6H8O7
Molecular Weight	697.8547
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.[H][C@@]12CC[C@H](CCOC3=CC=C(CN(CC)CC)C=C3OC)[C@@]1(C)CC[C@]4([H])C5=C(C[C@@H](C)[C@@]24[H])C=C(O)C=C5

InChI

InChIKey=VOHOCSJONOJOSD-SCIDSJFVSA-N

InChI=1S/C33H47NO3.C6H8O7/c1-6-34(7-2)21-23-8-13-30(31(19-23)36-5)37-17-15-25-9-12-29-32-22(3)18-24-20-26(35)10-11-27(24)28(32)14-16-33(25,29)4;7-3(8)1-6(13,5(11)12)2-4(9)10/h8,10-11,13,19-20,22,25,28-29,32,35H,6-7,9,12,14-18,21H2,1-5H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t22-,25-,28-,29+,32-,33-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C6H8O7
Molecular Weight	192.1235
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C33H47NO3
Molecular Weight	505.7312
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22045595 | https://www.ncbi.nlm.nih.gov/pubmed/29434492

TAS-108 (also known as SR-16234) is a selective estrogen receptor modulator (SERM) and has been reported to have estrogen receptor (ER) α antagonistic activity and a strong affinity with a weak partial agonistic activity to ERβ receptor. It is known that ERs play a central role in the diverse actions of estrogen. TAS-108 was studied in phase II clinical trials to treat recurrent or recurrent inoperable breast cancer. In addition, TAS-108 participated in Japan in a phase II clinical trial in Endometriosis patients. The phase III studies are being planned with the drug.

Originator

Approval Year

PubMed

Title	Date	PubMed
Both N- and C-terminal transactivation functions of DNA-bound ERalpha are blocked by a novel synthetic estrogen ligand.	2003 Dec 19	14680815
TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.	2005 Jan 1	15671561
Safety, tolerability and pharmacokinetics of TAS-108, a novel anti-oestrogen, in healthy post-menopausal Japanese women: a phase I single oral dose study.	2009 May	19175362
Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer.	2012 Jul 1	22045595

Sample Use Guides

In Vivo Use Guide

TAS-108 was administered daily at a dose of 40 mg, 80 mg, or 120 mg to postmenopausal patients with locally advanced, or inoperable, or metastatic hormone-receptor positive breast cancer

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:58:50 UTC 2023` Edited by `admin` on `Fri Dec 15 15:58:50 UTC 2023`
Record UNII	9B29N23K7E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TAS-108

Code

English

TAS-108 CITRATE

Code

English

19-NORPREGNA-1,3,5(10)-TRIEN-3-OL, 21-(4-((DIETHYLAMINO)METHYL)-2-METHOXYPHENOXY)-7-METHYL-, (7.ALPHA.)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1) (SALT)

Systematic Name

English

HLX-801

Code

English

SR-16234

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C481